EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation

Moazzam Shahzad, Muhammad Kashif Amin iD, Polina Bellman, Joe Al-Ramahi, Jawad Noor, Abhinav Vyas, Zahra Mahmoudjafari, Matthew McGuirk, Shaun DeJarnette, Nausheen Ahmed, Al-Ola Abdallah, Leyla Shune und 4 weitere

Transfusion · 2024

DOI: 10.1111/trf.17909 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Transfusion, 2024. Verfasst von Moazzam Shahzad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Filgrastim, Hematopoietic Stem Cell Mobilization, Biosimilar Pharmaceuticals, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivestym, a biosimilar granulocyte colony‐stimulating factor (G‐CSF) to the originator filgrastim (Neupogen), is now being used for the mobilization of peripheral blood stem cells (PBSC) in allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We aim to compare the efficacy of Nivestym and Neupogen for PBSC mobilization in healthy allogeneic donors.

Methods

We conducted a retrospective single‐center study including 541 adult allo‐HSCT donors receiving Nivestym (January 2013–July 2020), or Neupogen (July 2020–June 2023) for donor PBSC mobilization. Bivariate analysis was conducted using SPSS version 28. Statistical significance was determined at a p ‐value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FilgrastimHematopoietic Stem Cell MobilizationBiosimilar PharmaceuticalsHematopoietic Stem Cell TransplantationPeripheral Blood Stem CellsHumansAdultMiddle AgedMaleFemaleRetrospective StudiesAgedAdolescentYoung AdultTransplantation, HomologousPeripheral Blood Stem Cell Transplantation

Stichwörter der Autor:innen

CD34+ countallogeneic stem cell transplantgranulocyte colony‐stimulating factorstem cell mobilization

Substanzen

FilgrastimBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
  • Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.

ORCID-Profile: Muhammad Kashif Amin, Muhammad Umair Mushtaq

Zitieren

APA

Shahzad, M., Amin, M. K., Bellman, P., Al-Ramahi, J., Noor, J., Vyas, A., Mahmoudjafari, Z., McGuirk, M., DeJarnette, S., Ahmed, N., Abdallah, A. O., Shune, L., Singh, A. K., McGuirk, J. P., Abhyankar, S., & Mushtaq, M. U. (2024). Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation. Transfusion. https://doi.org/10.1111/trf.17909

Vancouver

Shahzad M, Amin MK, Bellman P, Al-Ramahi J, Noor J, Vyas A, et al. Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation. Transfusion. 2024. doi:10.1111/trf.17909

BibTeX
@article{Shahzad2024,
  author = {Shahzad, Moazzam and Amin, Muhammad Kashif and Bellman, Polina and Al-Ramahi, Joe and Noor, Jawad and Vyas, Abhinav and Mahmoudjafari, Zahra and McGuirk, Matthew and DeJarnette, Shaun and Ahmed, Nausheen and Abdallah, Al-Ola and Shune, Leyla and Singh, Anurag K and McGuirk, Joseph P and Abhyankar, Sunil and Mushtaq, Muhammad Umair},
  title = {Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17909}
}
Kostenlos starten →